Personalized mRNA Vaccine Cuts Melanoma Recurrence Risk by 42% in Landmark Phase‑3 Trial

A joint effort by Merck and Moderna has produced a breakthrough in the fight against melanoma, the deadliest form of skin cancer. In the Phase 3 INTerpath‑001 trial, a personalized mRNA‑based vaccine called Intismeran Autogene, when combined with the immune‑checkpoint inhibitor pembrolizumab, lowered the risk of disease recurrence or death by 42 % compared with pembrolizumab alone. The study enrolled 1,137 high‑risk melanoma patients who had undergone complete surgical resection. Participants were randomly assigned to receive either pembrolizumab monotherapy or the same drug together with the individualized vaccine. After a median follow‑up of 24.6 months, 82.2 % of the combination‑treated group remained recurrence‑free, versus 70 % in the control arm. The vaccine also cut the risk of distant metastasis by 38 %. Intismeran Autogene is crafted from a tumor biopsy taken from each patient. Researchers sequenced the tumor DNA, identified up to three neo‑antigen mutations unique to the individual, and encoded these signatures into an mRNA construct that trains the immune system to recognize and destroy cancer cells. Safety signals were mild and comparable to earlier phases, with fever, fatigue and injection‑site pain being the most common adverse events. “These results are transformative and could shift the paradigm for early‑stage melanoma treatment,” said Georgina Long, medical director of the Australian Melanoma Institute and principal investigator of the trial. Independent experts such as Eva Muñoz Couselo echoed the sentiment, noting that this is the first Phase III proof that a truly individualized therapeutic vaccine can amplify the efficacy of standard immunotherapy. The implications extend far beyond melanoma. Similar personalized mRNA strategies are already being tested in pancreatic and other solid tumors, suggesting a new frontier for cancer care. Yet, scaling production, controlling costs, and securing regulatory approval remain formidable challenges. If these hurdles are overcome, the approach could usher in a new era of bespoke oncology treatments.